Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-PROTKT Phase 3 trial of vicadrostat + empagliflozin in high CV-risk type 2 diabetes
ChiCTR2500109496Phase 3Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM), hypertension (HTN), cardiac morbidity and 2 more comparing Vicadrostat + empagliflozin with Placebo + empagliflozin (2 arms). Primary endpoint: Composite primary endpoint: time to first cardiovascular death or heart failure event (HHF or urgent HF visit). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
vicadrostatempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)cardiac morbidityheart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR2500109496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109496.